StockData
Bioxytran, Inc logo

Bioxytran, Inc (BIXT) stock

BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30
$0.02−0.00 (-3.95%)

Close on Oct 19, 2026Market cap $2.56MP/E –Yield –

Earnings

Bioxytran's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Bioxytran's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Bioxytran has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Bioxytran puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Bioxytran filed with the SEC as exhibits to Form 8-K or 6-K

  1. Secures Attested Free Sale Certification for A-SUQAR ® , Opening the Path to the UAE and Gulf Markets
    News
  2. Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID,
    News
  3. Inc. Completes $1.2 Million Private Placement
    News
  4. Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
    News
  5. Inc. Announces Commercial Distribution Agreement
    News
  6. REPORTS POSITIVE PHASE 2 RESULTS
    News
  7. Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
    News
  8. Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
    News
  9. Bioxytran Measures the Presence of Carbon Monoxide
    News
  10. Launches Joint Venture with the Heme Foundation for Development of a Universal Oxygen Carrier
    News
  11. BXT-25 Drug Acts as a Universal Oxygen Carrier Like Hyperbaric Oxygenation for Stroke & Alzheimer’s Patients
    News
  12. Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
    News
  13. Expands Institutional Investor Base with an additional $500,000 Equity Investment
    News
  14. Receives Approval to Initiate Trials with ProLectin-I
    News
  15. Establishes Indian Subsidiary in Preparation of Commercialization
    News

See a number that looks wrong?